NCT03475953 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03475953
Title	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Acronym	REGOMUNE
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Institut Bergonie
Indications	transitional cell carcinoma triple-receptor negative breast cancer stomach carcinoma esophageal carcinoma differentiated high-grade thyroid carcinoma malignant pleural mesothelioma lung non-squamous non-small cell carcinoma pancreatic endocrine carcinoma gastrointestinal stromal tumor lung non-small cell carcinoma gastric neuroendocrine neoplasm colorectal cancer hepatobiliary system cancer renal carcinoma Advanced Solid Tumor sarcoma
Therapies	Avelumab + Regorafenib
Age Groups:	senior \| adult
Covered Countries	FRA

Filter rows:

Showing 1 to 7 of 7 entries

Facility	Status	City	Zip	Country	Details
Centre Hospitalier Régional Universitaire - CHU Morvan	RECRUITING	Brest	29200	France	Details
Centre Léon Bérard	RECRUITING	Lyon	69008	France	Details
Institut Bergonié	RECRUITING	Bordeaux	33076	France	Details
Institut Curie	RECRUITING	Paris	75248	France	Details
Institut de Cancérologie de Montpellier	RECRUITING	Montpellier	34298	France	Details
Institut Gustave Roussy	RECRUITING	Villejuif	94800	France	Details
IUCT Oncopôle - Institut Claudius Regaud	RECRUITING	Toulouse	31059	France	Details

Showing 1 to 7 of 7 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03475953Clinical Trial Detail